You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
ST百花(600721.SH)擬定增募資不超4.299億元 用於MAH制度下藥品的研發及產業化項目等
格隆匯 06-08 19:25

格隆匯6月8日丨ST百花(600721.SH)披露2020年非公開發行A股股票預案,擬非公開發行股票數量不超過此次發行前總股本(已考慮扣除張孝清因上市公司前次重大資產重組業績承諾未實現,向上市公司支付補償股份25,252,039股,即:375,134,355股)的30%,即11254.03萬股;發行價為3.82/股。

募集資金總額不超過4.299億,扣除發行費用後,1.75億元用於MAH制度下藥品的研發及產業化項目,1.15億元用於小分子創新藥物項目,0.3億元用於多肽創新藥及PDC藥物研項目,1.099億元用於補充流動資金。

發行對象為公司控股股東的全資子公司新疆華凌國際醫療產業發展有限公司以及廣西錦藍投資管理中心(有限合夥)復思資產管理(北京)有限公司名戰略投資者,共3名特定對象。

疆華凌國際醫療產業發展有限公司以現金認購此次非公開發行的股份,廣西錦藍投資管理中心(有限合夥)復思資產管理(北京)有限公司以其管理的契約式基金項下的財產認購此次非公開發行的股份

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account